In premarket trading session, Tonix Pharmaceuticals Holding Corp. (TNXP) stock had surged by 2.46% to $1.25 at last check. TNXP stock previously closed the session at $1.22 on Friday. The stock volume traded 5.76 million shares. In the past year up to date TNXP stock have risen by 93.01% however in the past week they shed by -8.27%. In the past three and six months, the TNXP stock had plunged -15.86%, while adding 109.44% respectively. Furthermore, Tonix Pharmaceutical is currently valued in the market at $401.70 million and has 326.51 million outstanding shares.

Here’s what you need to know about TNXP stock

Tonix Pharmaceutical Holding  Corp, is a clinical stage biopharma company that specifically focuses on the treatments and prevention of human diseases along with the alleviation of the pain and wounds. TNXP stock does this through developing and licensing small molecules and biologics for prevention of infectious diseases. Furthermore, the company addresses a certain immunosuppression which can aggravate the immune fight response of the body, autoimmune diseases and cancer. Furthermore, the company focuses on the treatment of pain, neurologic, psychiatric and addiction conditions through its proprietary design and manufacturing of leading candidates.

Currently the company’s lead vaccine candidate is TNX-1800 which is a live replicating version of vaccine that instills the horsepox viral vector as a platform to protect against the COVID-19. Furthermore the company has other vaccine candidates that also replicate the same horsepox live vaccine virus to serve as a vector platform and prevent against monkeypox, smallpox and COVID-19 prevention. Its items incorporate TNX-1300 for the treatment of cocaine inebriation; TNX-601 CR for despondency problem, PTSD, and neurocognitive brokenness from corticosteroids; and TNX-1900 for headache and craniofacial torment treatment. Its preclinical pipeline incorporates TNX-1600 for PTSD, despondency, and consideration shortfall hyperactivity issue; TNX-1700 for gastric and pancreatic malignant growths; TNX-701 for radioprotection; TNX-1200, a smallpox immunization; TNX-1500, a monoclonal counter acting agent against CD40-L for organ relocate dismissal autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi disorder. It additionally creates TNX-2100, a COVID-19 skin test. It has cooperation concurrences with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The organization was fused in 2007 and is settled in Chatham, New Jersey.

The long term potential of TNX-102 as COVID treatment

TNXP stock had announced today that it is aiming to develop the TNX-102 SL for potential treatment of long Covid Syndrome. This condition is officially known as Post-Acute Sequelae of Covid-19 (PASC). The CNS candidate is also for the treatment of aggravated Alzheimer disease, PTSD, and alcohol disorder, known as TNX-102 SL which is formulation of cuclobenzaprine in sublingual tablets for the treatment of fibromyalgia as well.

In the third quarter of 2021, there will be meeting with the U.S Food and Drug Administration for the potential design of the Phase 2 study of TNX-102 SL which will be pivotal for the overall clinical development of the CNS candidate for its further indicated use as Long COVID treatment.TonixPharamceuticals Holding Corp. found out about the pharmacodynamic movement of TNX-102 SL from more than 1,000 members who have been or are taken on its fibromyalgia preliminaries to date. Long COVID has been contrasted with fibromyalgia as a result of the normal indications of rest unsettling influence, diligent torment, weariness, and cerebrum haze.

TNX-102 SL is in mid-Phase 3 advancement for the treatment of fibromyalgia, for which between time examination aftereffects of the second potential significant investigation are expected in the second from last quarter of 2021, and topline results are in the principal quarter of 2022.